CD9 and neoplasm: Immunohistofluorescence imaging of tumor sections revealed marked increases in tumor-infiltrating T cells for BP-αCD3-αEGFR-ARC Exos treatment group in comparison with PBS and CD9-CD38/αCD3-αEGFR Exos groups (Supplementary Fig. 25).